For US Healthcare Professionals Only
For US Healthcare Professionals Only
REACH2: Timing by treatment initiation
My top treatment goal for patients with steroid-refractory acute GVHD is getting a complete response.
Pashna Munshi, MD, GVHD Expert
Grade 2 patients on Jakafi had ~3x higher ORR2
REACH2: For all grades studied, ORRs at day 28 were higher with Jakafi vs control therapy2
aGVHD=acute graft-versus-host disease; CI=confidence interval; CR=complete response; OR=odds ratio; ORR=overall response rate; PR=partial response; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation.
Phase 2 studya
Phase 3 studyc
In both studies, SR aGVHD was defined as disease progression after 3 days of high-dose systemic steroid treatment, lack of improvement after 7 days of such treatment, or failure to successfully taper steroid
aGVHD=acute graft-versus-host disease; BID=twice daily; GI=gastrointestinal; MAGIC=Mount Sinai Acute GVHD International Consortium; ORR=overall response rate; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SR=steroid-refractory.
aGVHD=acute graft-versus-host disease; BOR=best overall response; CI=confidence interval; CR=complete response; DOR=duration of response; GI=gastrointestinal; OR=odds ratio; ORR=overall response rate; PR=partial response; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SR=steroid-refractory.
References: 1. Socié G, Xue Z, Bhatt V, Galvin J, Mohty M. Early versus late treatment with ruxolitinib in patients with steroid-refractory acute graft-versus-host disease: a post hoc analysis from the randomized phase 3 REACH2 study. Blood. 2022;140(suppl 1):4765-4766. 2. Zeiser R, von Bubnoff N, Butler J, et al; for the REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-1810. Supplementary appendix available at: https://www.nejm.org/doi/10.1056/NEJMoa1917635. 3. Data on file. Incyte Corporation. Wilmington, DE. 4. Jakafi [package insert]. Wilmington, DE: Incyte Corporation. 5. Jagasia M, Perales MA, Schroeder MA, et al; for the REACH1 Study Group. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135(20):1739-1749. Supplementary appendix available at: https://ashpublications.org/blood/article/135/20/1739/452638/Ruxolitinib-for-the-treatment-of-steroid.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.